|
|
Daniel J. Rader
J Clin Invest. 2006;
116(12):3090
doi:10.1172/JCI30163
Abstract |
Full text
| PDF
H
DL metabolism represents a major target for the development of therapies intended to reduce the risk of atherosclerotic cardiovascular disease. HDL metabolism is complex and involves dissociation of HDL apolipoprotein and HDL cholesterol metabolism. Advances in our understanding of the molecular regulation of HDL metabolism, macrophage cholesterol efflux, and HDL function will lead to a variety of novel therapeutics.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(129)
| Title and authors |
Publication |
Year |
A rapid method for cross-species quantitation of apolipoproteins A1, B48 and B100 in plasma by ultra-performance liquid chromatography/tandem mass spectrometry : Quantitation of apolipoproteins A1, B48 and B100 in plasma
Michael E. Lassman, Theresa M. McLaughlin, Elizabeth P. Somers, Alice C. Stefanni, Zhu Chen, Beth Ann Murphy, Kathleen K. Bierilo, Amy M. Flattery, Kenneth K. Wong, Jose M. Castro-Perez
|
Rapid Commun. Mass Spectrom.
|
2012 |
Lipoprotein distribution and serum concentrations of 7α-hydroxy-4-cholesten-3-one and bile acids: effects of monogenic disturbances in high-density lipoprotein metabolism
Carine Steiner, Adriaan G. Holleboom, Ratna Karuna, Mohammad M. Motazacker, Jan Albert Kuivenhoven, Ruth Frikke‑Schmidt, Anne Tybjaerg‑Hansen, Lucia Rohrer, Katharina M. Rentsch, Arnold von Eckardstein
|
Clin. Sci.
|
2012 |
Monitoring Cyp2b10 mRNA expression at cessation of 2-year carcinogenesis bioassay in mouse liver provides evidence for a carcinogenic mechanism devoid of human relevance: the dalcetrapib experience
J.C. Hoflack, L. Mueller, S. Fowler, A. Braendli-Baiocco, N. Flint, O. Kuhlmann, T. Singer, A. Roth
|
Toxicology and Applied Pharmacology
|
2012 |
New lipid-lowering drugs: an update : New lipid drugs
A. S. Wierzbicki, T. C. Hardman, A. Viljoen
|
International Journal of Clinical Practice
|
2012 |
The Association between Apolipoprotein A-II and Metabolic Syndrome in Korean Adults: A Comparison Study of Apolipoprotein A-I and Apolipoprotein B
Dong Won Yi, Dong Wook Jeong, Sang Yeoup Lee, Seok Man Son, Yang Ho Kang
|
Diabetes Metab J
|
2012 |
ApoA-1 mimetic restores adiponectin expression and insulin sensitivity independent of changes in body weight in female obese mice
J S Marino, S J Peterson, M Li, L Vanella, K Sodhi, J W Hill, N G Abraham
|
Nutr Diab
|
2012 |
Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease
Christian Besler, Thomas F. Lüscher, Ulf Landmesser
|
EMBO Mol Med
|
2012 |
Novel HDL-directed pharmacotherapeutic strategies
Emil M. deGoma, Daniel J. Rader
|
Nat Rev Cardiol
|
2011 |
Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease
Christian Besler, Kathrin Heinrich, Lucia Rohrer, Carola Doerries, Meliana Riwanto, Diana M. Shih, Angeliki Chroni, Keiko Yonekawa, Sokrates Stein, Nicola Schaefer, Maja Mueller, Alexander Akhmedov, Georgios Daniil, Costantina Manes, Christian Templin, Christophe Wyss, Willibald Maier, Felix C. Tanner, Christian M. Matter, Roberto Corti, Clement Furlong, Aldons J. Lusis, Arnold von Eckardstein, Alan M. Fogelman, Thomas F. Lüscher, Ulf Landmesser
|
J. Clin. Invest.
|
2011 |
High-density lipoprotein metabolism in human apolipoprotein B100transgenic/brown adipose tissue deficient mice: a model of obesity-induced hyperinsulinemia
Sarah J. Ehlers, Stephanie M. Larson, Heather E. Rasmussen, Young-Ki Park, Ji-Young Lee
|
Appl. Physiol. Nutr. Metab.
|
2011 |
|
